Remidio Innovative Solutions has announced the launch of Neubo 130, an ultra-widefield neonatal retinal imaging system developed for precision diagnostics in neonatal retinal conditions including Retinopathy of Prematurity (ROP).
According to the company, India records more than three million premature births annually, which would translate to approximately 15 million retinal examinations if every newborn were screened according to clinical protocol. The current availability of ROP specialists remains limited, creating a gap in early detection and intervention. The Neubo 130 system has been designed to address this requirement through technology-supported screening.
The system is built for use in hospitals and neonatal intensive care units. It combines optical engineering with edge artificial intelligence to support real-time ROP detection without the need for internet connectivity. Neubo 130 features a 130° field of view, through-the-lens illumination, and light-shaping technology to maintain consistent retinal brightness and provide peripheral visualisation for clinical decision-making.
Key features include uniform illumination, reduced glare, and compatibility with pupils sized 3 mm and above. The device supports bedside triage with offline AI assistance for ROP and plus-disease evaluation, and offers a standardised workflow to reduce missed cases. Auto-montage capability aligns multiple gaze positions into a single 130° composite image. The platform also supports remote collaboration through telemedicine and cloud integration.
Dr. Anand Sivaraman, CEO of Remidio, said, “The launch of Neubo 130 marks a major step forward in neonatal eye care. This platform is our bet on certainty, reframing ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bedside, we move from ‘screening when possible’ to ‘protecting vision as standard’.”
Dr. Anand Vinekar, Professor and Head, ROP Services, Narayana Nethralaya, and Program Director, KIDROP, said, “With affordable imaging and AI-driven triage systems like Remidio’s NEUBO 130, we can bring early and accurate ROP detection to even the most remote centers. The future of screening is simple, intelligent, and accessible – empowering every healthcare worker to protect a baby’s vision from the very first exam.”
Neubo 130 weighs under 500 grams, provides 2.4 MP imaging resolution, and operates on an offline AI workflow. The device expands Remidio’s portfolio of ophthalmic technology utilised across 55 countries. The company reports that its devices have supported screening for more than 16 million patients globally.